Durvalumab and Oleclumab in Resectable PDAC
Abroad (travel likely)RecruitingPHASE2
Conditions
Pancreatic Ductal Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact: Study coordinator (Malcolm Moore, MD)Contact: Principal Investigator (Malcolm Moore, MD)
Study leads
Malcolm Moore, MD
Principal Investigator
Princess Margaret Cancer Centre/University Health Network